If administered prior to infection, AnxA1 plays an immunomodulatory role that is beneficial to the host, expanding the AM pool via GM-CSF production and protecting animals against IAV, while its presence during the course of an infection facilitates viral replication in different phases of the viral life cycle [85,92,117]. Here, CSF2 is linked to infection.